cjc 1295 ipamorelin synergy gh release multiple Peptide therapy designed to help your body do what it was built to do — recover, repair, and perform. CJC-1295 and support the body's natural growth-hormone under physician supervision, helping CJC-1295 No DAC + Ipamorelin

1998 (PMID 9849822) characterized ipamorelin as the first selective GHS without cortisol/prolactin elevation in rat and swine models

(Immune modulation with thymosin alpha-1 treatment.) Background mechanistic and clinical-trial sources only

By enhancing lipolysis, Ipamorelin aids in the utilization of fat stores for energy, potentially leading to reductions in body fat percentage

Regulatory and compounding status All four compounds share a broadly similar regulatory landscape in the United States as of 2026: None are FDA-approved as finished drug products for therapeutic use All are classified as WADA S2 prohibited substances year-round All four have 503A compounding status of Under Review, meaning the FDA Pharmacy Compounding Advisory Committee (PCAC) has nominated them for evaluation but final category assignments (Category 1 permitted for compounding

All orders are fulfilled by iHerb, which ships internationally to over 180 countries

Evidence based recommendations suggest selecting compounds based on specific research objectives not broad applications